GlassScriptPhysician profile
Brian Szabo
NPI 1174056741
$86,410.78
in general payments reported to CMS, 2019-2025
20 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.98 · 2020: $20.52 · 2021: $116 · 2022: $670 · 2023: $733 · 2024: $11K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Grant: $15K · Food and Beverage: $3,448 · Travel and Lodging: $339 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $66,772.42 |
| Grant | $15,000.00 |
| Food and Beverage | $3,448.30 |
| Travel and Lodging | $339.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $61,457.41 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Johnson & Johnson Surgical Vision, INC. | $21,357.79 | 2024-2025 | Tecnis Iol, Compact Intuitiv, Tecnis Iol |
| Glaukos Corporation | $1,788.52 | 2022-2025 | Travoprost Intraocular Implant - Idose, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Alcon Vision LLC | $416.34 | 2022-2025 | Clareon, Eysuvis |
| Sight Sciences, INC. | $275.39 | 2021-2024 | Omni Surgical System |
| Horizon Therapeutics Plc | $164.70 | 2022-2023 | Tepezza |
| Abbvie INC. | $155.57 | 2022-2024 | Durysta, Xen Glaucoma Treatment System |
| Sun Pharmaceutical Industries INC. | $121.58 | 2021-2024 | |
| Johnson & Johnson Vision Care, INC. | $102.65 | 2023 | Acuvue |
| Bausch & Lomb Americas INC. | $99.79 | 2023-2025 | Envista Envy Iol, Totalvisc, Envista Mx60 Iol |
| Genentech USA, INC. | $93.99 | 2024-2025 | Vabysmo |
| Biotissue Holdings INC. | $77.54 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $67.06 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $51.49 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $44.55 | 2023-2025 | Dextenza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.13 | 2024-2025 | Tepezza |
| Dompe US, INC. | $29.98 | 2025 | Oxervate |
| Harrow Eye, LLC | $23.80 | 2024 | |
| Kala Pharmaceuticals, INC. | $20.52 | 2020 | |
| Mallinckrodt Enterprises LLC | $18.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Szabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.